BSH 2024 | What can clinicians do to address the impact of transfusion-dependent thalassemia on patients’ QoL?
Farrukh Shah, MBBS, FRCP, FRCPath, MD, University College London Hospitals, London, UK, outlines the impact that transfusion-dependent beta-thalassemia major has on the quality of life of patients and highlights how clinicians can tailor treatment to prevent complications, reduce symptom burden, and improve patient quality of life (QoL). This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Haemoglobinopathy work: National Haemoglobinopathy Registry (NHR); Advisory board: Bristol Myers Squibb, Novartis, Vertex; Lecture Fees: Bristol Myers Squibb, Novartis, Chesi, Vertex; Safety Monitoring Committee: Agios, Pharmacosmos.
